About The Study: Within the studied participants, there were clear absolute benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors on kidney, hospitalization, and mortality outcomes irrespective of diabetes status and level of urine albumin to creatinine ratio.
Corresponding Author: To contact the corresponding author, William G. Herrington, MD, email will.herrington@ndph.ox.ac.uk .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.20835)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American Society of Nephrology Kidney Week 2025 meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.20835?guestAccessKey=227a59f5-dd3f-47e5-a06e-6b6340fb2e54&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110725
JAMA